The severe acute respiratory syndrome (SARS) is a recently described condition caused by infection with a coronavirus (CoV) [@bib1] and is characterized by both an atypical pneumonia and efficient nosocomial transmission.

First recognized in March 2003, SARS spread across the globe, caused many major outbreaks, and had an overall mortality rate of 11%,[@bib2] but was successfully contained in \< 4 months. Although it has been \> 1 year since the illness was successfully contained, published data on the condition of those who survived the illness are limited. Several studies[@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9] have reported persistent symptoms, as well as radiologic and functional abnormalities during follow-up several weeks or months after hospital discharge, but the prevalence and severity of the long-term sequelae of SARS remain largely unknown. Because lung function is known to improve for up to 1 year after discharge from the hospital in survivors of other causes of acute lung injury,[@bib10], [@bib11] it is imperative that long-term studies of SARS survivors be conducted in order to determine the persistence of abnormalities in pulmonary function, and whether these abnormalities contribute to permanent impairment and disability. As the majority of patients with SARS survive the illness[@bib2] and medical personnel, physicians, nurses, and hospital workers are among those commonly infected in most countries,[@bib2] an additional requisite for the identification and quantification of morbidity among survivors may be for the consideration of awarding compensation.

The purpose of this study was to characterize the long-term pulmonary function and health status in a prospectively identified cohort of patients who survived SARS in Singapore.

Materials and Methods {#cesec10}
=====================

Patient Selection {#cesec20}
-----------------

There were 206 cases of SARS in Singapore reported to the World Health Organization as of June 26, 2003.[@bib12] According to the World Health Organization case definition, *probable SARS* was diagnosed in all of these patients,[@bib13] and they were admitted to a single hospital (Tan Tock Seng Hospital). Survivors at 1 year after hospital discharge were eligible for enrollment in the study if they were ≥ 21 years of age. Patients were excluded from the study if they had been immobile before being admitted to hospital for SARS, had a history of pulmonary resection, or had a documented neurologic or psychiatric disease. We obtained written informed consent from patients prior to pulmonary function testing. This study was approved by the institutional ethics committee.

One hundred seventy-four consecutive SARS survivors were evaluated for this study ([Fig 1](#fig1){ref-type="fig"} ). Twenty-seven patients were excluded from the study for the reasons outlined in [Figure 1](#fig1){ref-type="fig"}. Seventeen patients were uncontactable, and 7 were overseas during the study period. Of the remaining 123 patients, 29 declined to participate in this study. The diagnosis of SARS was confirmed by a positive serology result for SARS-CoV in all except 1 of the 94 patients enrolled in this study.Figure 1Enrollment of patients and follow-up at 3 months after hospital discharge.

Pulmonary Function Testing {#cesec30}
--------------------------

Pulmonary function tests at 1 year after hospital discharge included spirometry, and measurements of total lung capacity and diffusing capacity of the lung for carbon monoxide (D[lco]{.smallcaps}). The protocol and equipment used for pulmonary function testing in this study were similar to those used in an earlier study[@bib9] that we conducted among recovered SARS patients. Spirometry was performed in accordance with recommended standards.[@bib14] All of the lung function tests were performed with the subjects seated and on the same day, but after patients had answered the health status questionnaire. FVC and FEV~1~ were measured with a clinical spirometer ( $\overset{˙}{\text{V}}$max 229; SensorMedics; Yorba Linda, CA). Total lung capacity and its subdivisions were measured by the nitrogen washout method with the spirometer, the testing adhered to standard criteria.[@bib15] The D[lco]{.smallcaps} was determined by the single-breath carbon monoxide technique[@bib16] using an infrared analyzer ( $\overset{˙}{\text{V}}$max 229). D[lco]{.smallcaps} was adjusted for a hemoglobin concentration of 14.6 g/dL for men and 13.4 g/dL for women.[@bib16] The spirometry, lung volumes, and D[lco]{.smallcaps} measurements were expressed as the percentages of predicted normal values using reference values taken from the prediction equations of Chia et al[@bib17] and Poh and Chia.[@bib18] The rating of impairment was made according to the American Thoracic Society (ATS) statement[@bib19] for the evaluation of impairment/disability secondary to respiratory disorders.

Health Status Measurement {#cesec40}
-------------------------

All of the eligible patients completed the Singapore-English version of the St. George respiratory questionnaire (SGRQ). The SGRQ is a standardized, self-administered, pulmonary-specific health status questionnaire containing 50 items and 76 weighted responses that is divided into three subscales, as follows: (1) symptoms (8 items); (2) activity (16 items); and (3) impacts (26 items). SGRQ scores were calculated using score calculation algorithms and missing data imputation recommended by its developer. For each subscale and for the overall questionnaire, scores range from 0 (no impairment) to 100 (maximum impairment). Mean scores obtained from a sample of persons (n = 74) between 17 and 80 years of age (mean age, 46 years) who had no history of respiratory disease (mean FEV~1~, 95%) served as reference values (P.W. Jones, MD; Scoring Manual of the SGRQ May 2003).

Statistical Analysis {#cesec50}
--------------------

Comparisons between groups were done with the Student *t* test for normally distributed continuous variables and with Mann-Whitney *U* tests for nonnormally distributed continuous variables. The linear regression model was used to study the association between known prognostic indicators of SARS and the 1-year pulmonary function outcomes, as well as the association between mechanical ventilation parameters during the acute illness and 1-year pulmonary function outcomes. Results were reported as the mean ± SD. The conventional level of statistical significance of 0.05 was used for all of the analyses.

Results {#cesec60}
=======

The baseline characteristics of the enrolled patients during their hospital admission for SARS are shown in [Table 1](#tbl1){ref-type="table"} . Forty-seven of the 94 patients (50%) were health-care workers. The mean (± SD) of the percentage of lung involvement based on the worst chest radiograph appearance during the acute illness using a scoring system similar to that of Wong et al[@bib20] was 40.6 ± 29.9%. Eleven patients (12%) required admission to the ICU, and the mean Pa[o]{.smallcaps} ~2~/fraction of inspired oxygen (F[io]{.smallcaps} ~2~) ratio among these patients in the ICU was 95.5 ± 65.6. Seven of these patients required mechanical ventilation. All seven of the patients had a Pa[o]{.smallcaps} ~2~/F[io]{.smallcaps} ~2~ ratio of ≤ 200 while receiving mechanical ventilation with a positive end-expiratory pressure of ≥ 5 cm H~2~O and evidence of airspace changes in all four of the quadrants on chest radiography. Overall, seven patients (7%) had a history of cigarette smoking. Nineteen patients (20%) had significant preexisting medical conditions. The four most common preexisting illnesses were hypertension (six patients), bronchial asthma (five patients), treated pulmonary tuberculosis (three patients), and diabetes mellitus (two patients).Table 1Characteristics of Patients With SARS During Hospital Admission (n = 94)[\*](#tbl1fn1){ref-type="table-fn"}VariableValuesAge, yr37.0 ± 12.0Male sex, %26Smokers, %7Preexisting medical illnesses, %20Preexisting pulmonary disease, %9Length of hospitalization, d13.0 ± 14.5Intensive care unit admission, %12Highest serum LDH level, U/L664.5 ± 454.5Ribavarin prescription, %54Steroids prescription, %10[^1]

Comparing the SARS survivors who were enrolled in this study with those who were not included, there was no significant difference with regard to age, gender, steroid exposure, or severity of the acute illness as indicated by the length of hospitalization, the requirement for intensive care or mechanical ventilation, and the highest recorded serum lactate dehydrogenase (LDH) level ([Table 2](#tbl2){ref-type="table"} ). Of the seven enrolled patients who had required mechanical ventilation, the mean duration of mechanical ventilation was 15 days compared with 11 days for the five patients who required mechanical ventilation among the 80 survivors who were not included in this study. The difference in the mean duration of mechanical ventilation between these two subsets of patients was not statistically significant (p = 0.443).Table 2Comparison of Enrolled SARS Survivors With Those Who Were Not Included in This Study[\*](#tbl2fn1){ref-type="table-fn"}VariablePatients Enrolled (n = 94)Patients Excluded (n = 80)p ValueAge, yr37.0 ± 12.037.6 ± 18.20.969Male sex, %26300.556Length of hospitalization, d13.0 ± 14.519.9 ± 21.40.187ICU admission, %12100.519Mechanical ventilation, %760.747Highest serum LDH level, U/L664.5 ± 454.5690.0 ± 440.50.305Steroids prescription, %1080.534[^2]

At 1 year after hospital discharge, with regard to respiratory symptoms that were present at least a few days a month over the preceding year, 28 patients (30%) had cough, 19 (20%) had increased sputum production, 28 (30%) had shortness of breath, and 7 (7%) had occasional wheezing. The mean body mass index of the group at this time was 23.4 ± 4.5.

The pulmonary function test results of the 94 patients are shown in [Table 3](#tbl3){ref-type="table"} . The group means of forced expiratory volumes, static lung volumes, and diffusion capacity were all within normal limits (*ie*, \> 80% predicted). However, several cases of abnormalities in FVC, FEV~1~, FEV~1~/FVC ratio, and D[lco]{.smallcaps} were detected. According to the ATS recommendations[@bib19] for evaluating respiratory impairment, 11 patients (12%) had mild impairment of FVC, 20 (21%) had mild impairment of FEV~1~, 5 (5%) had mild impairment of FEV~1~/FVC ratio, and 17 (18%) had mild impairment of D[lco]{.smallcaps}. There was one patient (1%) with moderate impairment of FVC, one patient (1%) with moderate impairment of FEV~1~/FVC ratio, and three patients (3%) with moderate impairment of D[lco]{.smallcaps}. Because there were cases of patients with impairment in more than one of the four variables, the number of patients with mild and moderate impairment according to the ATS recommendations was 30 (32%) and 5 (5%), respectively. [Table 4](#tbl4){ref-type="table"} shows the pulmonary function data of these 35 patients who had respiratory impairment. The majority of the impairment in FEV~1~ and FVC suggests a restrictive abnormality, but in only eight patients was the total lung capacity (TLC) \< 80% predicted. Two patients had obstructive abnormality with an FEV~1~/FVC ratio \< 70% predicted, and one of them (patient No. 17 in [Table 4](#tbl4){ref-type="table"}) had a history of poorly controlled bronchial asthma. The other patient (patient No. 12 in [Table 4](#tbl4){ref-type="table"}) had a significant history of cigarette smoking. None of the other patients who had respiratory impairment were current or ex-smokers. The preexisting medical conditions that may affect pulmonary function in the patients with pulmonary function abnormalities are as shown in [Table 4](#tbl4){ref-type="table"}.Table 3Results of Pulmonary Function Tests at 1 Year After Hospital Discharge (n = 94)[\*](#tbl3fn1){ref-type="table-fn"}VariableResultsFVC L2.9 ± 0.7 (1.7--5.4) % predicted99.1 ± 15.5 (53.0--131.0)FEV~1~ L2.5 ± 0.6 (1.3--4.3) % predicted93.4 ± 14.4 (61.0--119.0)FEV~1~/FVC, %85.6 ± 7.6 (59.0--99.0)TLC L4.3 ± 0.9 (2.7--6.9) % predicted98.4 ± 14.4 (68.0--133.0)RV L1.3 ± 0.4 (0.3--2.4) % predicted97.2 ± 31.3 (16.0--175.0)FRC L2.2 ± 0.6 (1.0--4.0) % predicted96.1 ± 19.4 (47.0--144.0)VC L3.0 ± 0.7 (1.7--5.5) % predicted103.0 ± 15.0 (66.0--135.0)D[lco]{.smallcaps} mL/min/mm Hg7.3 ± 1.8 (3.5--13.0) % predicted88.8 ± 15.2 (48.0--134.0)D[lco]{.smallcaps}/VA ratio mL/min/mm Hg1.7 ± 0.3 (0.8--2.6) % predicted84.6 ± 14.3 (43.0--127.0)[^3]Table 4Clinical and Pulmonary Function Data of Patients With Pulmonary Function Impairment (n = 35)[\*](#tbl4fn1){ref-type="table-fn"}Patient No.Age, yrPreexisting IllnessesFVCFEV~1~FEV~1~/FVC. %D[lco]{.smallcaps}TLC1301068273809822672759910568329Asthma79798969794438578849195551727185928065053619579847731051188848908378585856376937Asthma9988767896102310510697721131143857884919512699168606291135072759055791428105887973107152310711099711121642Pulmonary tuberculosis79748483751757Asthma, hypertension886259801181851767586134991943Hypothyroidism8979818089203110795837210521568282836678224578718298912322Pulmonary tuberculosis757496629724407569838477252687748185962649VHD, hypertension676686787827561028169821192854124102709691293412911382761263024131116867711731291017670105118323876779276823323848496758434358579867683356193105925482[^4]

[Table 5](#tbl5){ref-type="table"} shows the serial pulmonary function data of 17 patients in the present study who were detected to have abnormalities from among a group of patients who had been evaluated at 3 months after hospital discharge in an earlier study.[@bib9] The mean D[lco]{.smallcaps} improved significantly by 8.3% (p = 0.047) at 1 year, but no significant changes were detected in the other pulmonary function variables of these 17 patients.Table 5Serial Data of Patients With Pulmonary Function Impairment Assessed at 3 Months and Reassessed at 1 Year After Hospital Discharge (n = 17)[\*](#tbl5fn1){ref-type="table-fn"}Patient No.3 mo1 yrFVCFEV~1~FEV~1~/FVC, %D[lco]{.smallcaps}FVCFEV~1~FEV~1~/FVC, %D[lco]{.smallcaps}19190907297898311128977817087748185310993807810588797349078798497868189572718778676686786939288105886259807906461529310592548789094721021068791989919254756983841075769377848496751180828470797484831294100897012410982831378718380106107871121488869474115111938215767487657574966216117104826785798676178079878889798180[^5]

Comparing the pulmonary function of patients who required ICU care and mechanical ventilation during hospitalization for SARS with those who did not, there was no significant difference in FVC, FEV~1~, FEV~1~/FVC ratio, or D[lco]{.smallcaps} between the two groups. Using multivariate analysis to analyze the association between known prognostic indicators of SARS,[@bib2] namely, age, gender, comorbidity, serum LDH level, ribavarin level, and steroid use, and the 1-year pulmonary function outcomes, we found that only age was significantly associated with the FVC percent predicted (every year increase, −0.34; 95% confidence interval, −0.6 to −0.08; p = 0.01) and with the FEV~1~ percent predicted (every year increase, −0.26; 95% confidence interval, −0.5 to −0.01; p = 0.04), but none of the prognostic factors were significantly associated with the D[lco]{.smallcaps} percent predicted. Among patients who required intensive care and mechanical ventilation during the acute illness, there was no significant association among the duration of mechanical ventilation, the Pa[o]{.smallcaps} ~2~/F[io]{.smallcaps} ~2~ ratio on admission to the ICU, steroid usage, and the pulmonary function parameters at 1 year after hospital discharge. All 94 of the patients completed the SGRQ. Domain scores other than the symptoms domain of the SGRQ were significantly higher (*ie*, worse) than the population norms ([Table 6](#tbl6){ref-type="table"} ).Table 6SGRQ Domain Scores of SARS Survivors Compared With Healthy Subjects[\*](#tbl6fn1){ref-type="table-fn"}DomainSARS SurvivorsHealthy Subjectsp ValueTotal15.1 ± 16.16\< 0.001Symptoms15.1 ± 18.4120.104Activity22.7 ± 22.89\< 0.001Impacts10.7 ± 14.82\< 0.001[^6]

Discussion {#cesec70}
==========

Impaired pulmonary function is present in about one third of patients 1 year after their recovery from SARS. The most common pulmonary function impairment was of the FEV~1~ and D[lco]{.smallcaps}. As measured by the SGRQ, SARS survivors had significant worsening in health status compared with the healthy population.

To date, reported studies on the functional outcomes of patients during the recovery stage of SARS are limited,[@bib3], [@bib4], [@bib5], [@bib6], [@bib9] and none has evaluated the outcomes at a uniform 1-year time point. In assessing long-term outcomes after acute lung injury, it is important to attempt the consecutive enrollment of survivors with defined time points for study, because there is a possibility of bias toward the selection of sicker patients with abnormal pulmonary function test results if studies enrolled any patient who returned for a follow-up evaluation. In an earlier prospective study[@bib9] of pulmonary function tests in 46 recovered SARS patients at a uniform time point of 3 months after hospital discharge, we found 7 patients (15%) with mild impairment of FVC, 12 patients (26%) with mild impairment of FEV~1~, 17 patients (37%) with mild impairment of D[lco]{.smallcaps}, and 1 patient (2%) with moderate impairment of D[lco]{.smallcaps}. Overall, pulmonary function defects were detected in half of the recovered SARS patients at 3 months after hospital discharge. The finding in the present study of persistent pulmonary function abnormalities in a significant proportion of SARS patients 1 year after hospital discharge is notable, not only for the long-term follow-up and management of these patients but also as a highlight of the permanent respiratory impairment that can result from the acute infection. Viral pneumonia usually resolves without any clinical or radiologic sequelae, whereas SARS-related radiologic sequelae appear to be quite common among survivors, as observed by several studies.[@bib8], [@bib21]

The finding of higher prevalence of dynamic lung volume abnormalities than D[lco]{.smallcaps} impairment in the present study, together with the significant improvement in D[lco]{.smallcaps} but not dynamic lung volumes in serial lung function testing of a subset of our patients, suggest that D[lco]{.smallcaps} abnormalities can improve with time. In contrast, ventilatory abnormalities are more likely to persist in the long term. This appears to be in contrast to information from several reviews[@bib22], [@bib23] on survivors of the ARDS documenting the persistence of a mild reduction in D[lco]{.smallcaps} as the most common abnormality found in pulmonary function testing, and that D[lco]{.smallcaps} remained low in long-term follow-ups. Interestingly, all of the articles on ARDS survivors reporting normal lung volumes or very low rates of either obstruction or restriction were published earlier when cohorts were likely more heterogeneous, and lung injuries in the surviving population were most likely less severe.[@bib24], [@bib25], [@bib26] In more recent studies, the proportion of patients with ventilatory impairment has ranged constantly higher, from 18 to 33% for airway obstruction and from 15 to 45% for lung restriction.[@bib27], [@bib28], [@bib29], [@bib30] In particular, Neff et al[@bib31] have reported that residual restrictive and obstructive types of functional impairment remained common (25% of patients with each type) in survivors of severe ARDS, and only 12.5% of patients had impairment in D[lco]{.smallcaps}.

The exact pathologic cause(s) of the pulmonary dysfunction in recovered SARS patients is not known. Adverse long-term pulmonary sequelae of the ARDS include lung fibrosis, but untreated bronchiolitis obliterans-organizing pneumonia and bronchiolitis obliterans may also contribute to the physical morbidity in ARDS survivors.[@bib32] In addition, neuromuscular weakness may also contribute to the decline in pulmonary function.[@bib33] A recent study[@bib8] correlating high-resolution CT scan findings and pulmonary function in survivors of SARS during the early recovery phase (*ie*, 25 to 38 days after hospital discharge) found that FEV~1~, FVC, TLC, residual volume, and D[lco]{.smallcaps} correlated well with the severity of ground-glass opacification and fibrosis. The presence of fibrosis was associated with significantly lower pulmonary function variables. It would be interesting to compare structural and functional changes in survivors of SARS during late recovery to see whether a similar correlation persists and whether these changes are different from those observed in ARDS survivors whose condition is not related to SARS.

In contrast to the results of the earlier study[@bib5] among patients averaging 28 days in the posthospital discharge period, significantly worse scores were not found in the symptoms domain of the SGRQ among our SARS survivors at 1 year. This is likely attributable to an improvement in symptoms with time of recovery. In studies among survivors of ARDS, it is known that nearly all of the patients are symptomatic at hospital discharge, but there is significant improvement over the first year after ARDS in most patients.[@bib11] In addition, survivors of ARDS are also much less symptomatic than other patients with chronic lung disease.[@bib11] Nonetheless, the mean activity score of our patients measuring disturbances to their daily physical activity and their mean impacts score covering a wide range of disturbances of psychosocial function remain significantly worse compared with those in healthy subjects. Physical morbidity in SARS survivors may also stem from extrapulmonary causes. In an earlier study[@bib9] evaluating pulmonary function and exercise capacity among patients from the same cohort, we found no evidence of exercise limitation solely because of ventilatory constraints, and there were very few patients with significant oxygen desaturation during exercise. Hence, the disability represented by an increased (*ie*, worse) score on the SGRQ activity domain in the present study is not likely to be specific to intrinsic pulmonary dysfunction, especially given that pulmonary dysfunction in our patients is modest, but may instead reflect any cause of impaired physical functioning, such as muscle loss/weakness or neuromuscular disease. Corticosteroid myopathy may be a contributory factor, although only a small percentage of our patients had received treatment with steroids during their acute illness.

There are several limitations of this study that we would like to acknowledge. First, the heterogeneity of acute lung disease encompassed by the case definition of SARS may account for the observed variation in pulmonary and extrapulmonary sequelae among our patients. Second, the proportion of patients who declined evaluation may have led to a bias toward the selection of sicker patients with abnormal pulmonary function. This is likely, because most of the patients who declined participation in the study offered a lack of symptoms and inconvenience as the main reasons for doing so. Third, evaluations of arterial blood gas levels and exercise testing were not performed in this study. However, we did not anticipate that there was significant hypoxemia in these patients, because none of them was found to have hypoxemia or was assessed as requiring oxygen supplementation during routine follow-up. Cardiopulmonary responses to exercise in SARS survivors had been evaluated in an earlier study[@bib9] at 3 months after hospital discharge, but we do not have any longer term data on this. Fourth, only a respiratory-specific measure of health status was used in this study. A generic health status measure, such as the Medical Outcomes Study 36-item short-form health survey, would have provided a more global assessment of the patients, especially with regard to their role limitations as a result of emotional problems, mental health, bodily pain, and general health perceptions. The interaction of the data obtained from generic and disease-specific measures of health status may also have helped to determine the contributions of pulmonary and nonpulmonary factors to the long-term health status of SARS survivors.

In summary, 1 year after recovery from SARS, persistent pulmonary function impairment was found in about one third of patients. The health status of SARS survivors was also significantly worse compared with that of the healthy population.
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[^1]: Values given as mean ± SD or No., unless otherwise indicated.

[^2]: Values given as mean ± SD or No., unless otherwise indicated.

[^3]: Values given as mean ± SD (range). FRC = functional residual capacity; RV = residual volume; VA = alveolar volume; VC = vital capacity.

[^4]: Values given as % predicted, unless otherwise indicated. VHD = valvular heart disease.

[^5]: Values given as % predicted, unless otherwise indicated.

[^6]: Values given as mean ± SD, unless otherwise indicated.
